Atypical Diaphyseal Femur Fractures in Patients with Prolonged Administration of Bisphosphonate Medication for Osteoporosis

Horning, Joel; Czajka, John; Uhl, Richard L.

doi:10.3928/01477447-20101021-21

Search citation statements

Order By: Relevance

Paper Sections

Select...

Preventing Atypical Hip Fracture After Long-term Bisphosphon1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2013

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 30 publications

(14 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…were approved by the Food and Drug Administration in 1995 (Hornig, Czajka, & Uhl, 2010) and have been used both continuously and intermittently since then. Bisphosphonates are antiresorptive drugs, which inhibit bone resorption.…”

Section: Preventing Atypical Hip Fracture After Long-term Bisphosphonmentioning

confidence: 99%

Preventing Atypical Hip Fracture After Long-Term Bisphosphonate Use

Ortega¹

2013

Orthopaedic Nursing

View full text Add to dashboard Cite

In recent years there have been an increasing number of case reports linking long-term bisphosphonate use with atypical fractures of the hip. This link led to a synthesis of the evidence regarding this relationship. On the basis of the results, a doctoral project called "Preventing Atypical Hip Fracture After Long-Term Bisphosphonate Use" was created. The tool termed HIPS developed by the project leader helps providers identify those patients who are at potential risk and refer them to their primary care providers when appropriate. The tool also helps educate patients about symptoms of atypical fracture. The goal was to improve preventive strategies of adult providers to screen for patients at risk of atypical hip fracture. Results showed that an educative session modeled around the HIPS tool improved provider awareness about the link between bisphosphonates and atypical hip fractures. An improved willingness to screen for risk, refer to primary care providers, and educate patients about the symptoms of atypical fractures also showed improvement.

show abstract

Section: Preventing Atypical Hip Fracture After Long-term Bisphosphonmentioning

confidence: 99%

Preventing Atypical Hip Fracture After Long-Term Bisphosphonate Use

Ortega¹

2013

Orthopaedic Nursing

View full text Add to dashboard Cite

show abstract

Atypical Diaphyseal Femur Fractures in Patients with Prolonged Administration of Bisphosphonate Medication for Osteoporosis

Cited by 1 publication

References 30 publications

Preventing Atypical Hip Fracture After Long-Term Bisphosphonate Use

Preventing Atypical Hip Fracture After Long-Term Bisphosphonate Use

Contact Info

Product

Resources

About